Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency

J Rheumatol. 1990 Sep;17(9):1222-5.

Abstract

The deficiency of second component of complement (C2d) is the most common hereditary complement deficiency. Patients with C2 deficiency are frequently associated with an auto-immune disease process, in particular, systemic lupus erythematosus (LE)-like syndrome and/or vasculitic syndrome or bacterial infections. C2d has been associated with the LE subset of subacute cutaneous LE (SCLE), the presence of anti-Ro (SSA) antibodies, and the human leukocyte antigen (HLA) types A10, B18, DR2. We describe the clinical, serologic and immunogenetic data in a patient with manifestations of Sjögren's syndrome who developed urticarial vasculitis and photosensitive annular SCLE which were effectively treated with oral dapsone. Our case illustrates the dynamic nature of LE.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Adult
  • Complement C2 / deficiency*
  • Dapsone / administration & dosage
  • Dapsone / therapeutic use*
  • Female
  • Humans
  • Lupus Erythematosus, Cutaneous / complications
  • Lupus Erythematosus, Cutaneous / drug therapy*
  • Lupus Erythematosus, Cutaneous / metabolism
  • Lupus Erythematosus, Cutaneous / pathology
  • Sjogren's Syndrome / complications
  • Sjogren's Syndrome / metabolism
  • Sjogren's Syndrome / pathology
  • Urticaria / complications
  • Vasculitis / complications
  • Vasculitis / drug therapy*
  • Vasculitis / metabolism
  • Vasculitis / pathology

Substances

  • Complement C2
  • Dapsone